Key result
Advanced pulmonary hypertension therapy linked to ~69% lower mortality in Eisenmenger syndrome.
Observational (n=167)
Yes
Odds Ratio: 0.31
Arrhythmias are common in adults with Eisenmenger syndrome and are associated with increased risk of sudden death, while advanced pulmonary hypertension therapies may reduce all-cause mortality.
May support advanced PH therapy consideration in Eisenmenger syndrome; leaves open antiarrhythmic risks pending prospective trials.
BACKGROUND: Patients with Eisenmenger syndrome have a shorter lifespan than the general population. A significant proportion develop arrhythmia and some, sudden death. OBJECTIVE: The aims of this study were to characterize the frequency, type and effects of arrhythmias in adult patients with Eisenmenger's syndrome and to identify risk factors for arrhythmias. METHODS: This retrospective study included patients aged ≥ 18 years of age with Eisenmenger's syndrome from three institutions. Arrhythmias were noted from electrocardiograms and Holter study reviews. RESULTS: A total of 167 patients, 96 females, 63 males (gender not available in 9 patients) were included in this study. The mean age was 38 ± 9 years (range: 18-63 years) with a majority in NYHA functional class II or III (57% and 32% respectively). Twenty-eight patients (17%) had significant tachyarrhythmia: paroxysmal supraventricular tachycardia (8 patients, 29%), atrial fibrillation (6 patients, 21%), atrial fibrillation and flutter (2 patients, 7%), nonsustained ventricular tachycardia (6 patients, 21%) and sustained ventricular tachycardia (6 patients, 21%). Among the entire study group, 26 patients (16%) were currently on antiarrhythmic therapy and 77 patients (49%) were on advanced therapies for pulmonary hypertension. Down syndrome was present in 78 patients (46%). There were 21 (13%) documented deaths, of which 8 (5%) were sudden death. Patients with arrhythmia were older [P = .01] and were more likely to have atrioventricular valvar regurgitation [Odds ratio: 4.33]. Advanced pulmonary hypertension therapy was associated with decreased all-cause mortality in logistic regression analysis [odds ratio: 0.31], while antiarrhythmic therapy was associated with sudden death [odds ratio: 6.24]. CONCLUSIONS: Arrhythmias are common among patients with Eisenmenger syndrome occurring in around 1 in 5 individuals and are associated with all-cause mortality and sudden death.
No takes yet. Share an insight, caveat, or question.
Baskar et al. (2017) conducted an observational in Eisenmenger syndrome (n=167). Advanced pulmonary hypertension therapy vs. No advanced pulmonary hypertension therapy was evaluated on All-cause mortality (OR 0.31). In adult patients with Eisenmenger syndrome, advanced pulmonary hypertension therapy was associated with decreased all-cause mortality (OR 0.31), whereas antiarrhythmic therapy was associated with sudden death (OR 6.24).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: